Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial

被引:451
作者
Erlandsson, Johan [1 ,2 ]
Holm, Torbjorn [1 ,2 ]
Pettersson, David [3 ,4 ]
Berglund, Ake [5 ]
Cedermark, Bjorn [1 ,2 ]
Radu, Calin [5 ]
Johansson, Hemming [6 ]
Machado, Mikael [7 ,8 ]
Hjern, Fredrik [7 ,8 ]
Hallbook, Olof [9 ]
Syk, Ingvar [10 ]
Glimelius, Bengt [5 ]
Martling, Anna [1 ,2 ]
机构
[1] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[2] Karolinska Univ Hosp, Ctr Digest Dis, Stockholm, Sweden
[3] Karolinska Inst, Dept Mol Med & Surg, Norrtalje, Sweden
[4] Norrtalje Hosp, Dept Surg, Norrtalje, Sweden
[5] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[6] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[7] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden
[8] Karolinska Inst, Ersta Hosp, Stockholm, Sweden
[9] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden
[10] Lund Univ, Dept Surg, Malmo, Sweden
基金
瑞典研究理事会;
关键词
POSTOPERATIVE CHEMORADIOTHERAPY; DELAYED SURGERY; FOLLOW-UP; CHEMOTHERAPY; CHEMORADIATION; METAANALYSIS; OXALIPLATIN; RECURRENCE; CARCINOMA; REGIMENS;
D O I
10.1016/S1470-2045(17)30086-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Radiotherapy reduces the risk of local recurrence in rectal cancer. However, the optimal radiotherapy fractionation and interval between radiotherapy and surgery is still under debate. We aimed to study recurrence in patients randomised between three different radiotherapy regimens with respect to fractionation and time to surgery. Methods In this multicentre, randomised, non-blinded, phase 3, non-inferiority trial (Stockholm III), all patients with a biopsy-proven adenocarcinoma of the rectum, without signs of non-resectability or distant metastases, without severe cardiovascular comorbidity, and planned for an abdominal resection from 18 Swedish hospitals were eligible. Participants were randomly assigned with permuted blocks, stratified by participating centre, to receive either 5 x 5 Gy radiation dose with surgery within 1 week (short-course radiotherapy) or after 4-8 weeks (short-course radiotherapy with delay) or 25 x 2 Gy radiation dose with surgery after 4-8 weeks (long-course radiotherapy with delay). After a protocol amendment, randomisation could include all three treatments or just the two short-course radiotherapy treatments, per hospital preference. The primary endpoint was time to local recurrence calculated from the date of randomisation to the date of local recurrence. Comparisons between treatment groups were deemed non-inferior if the upper limit of a double-sided 90% CI for the hazard ratio (HR) did not exceed 1.7. Patients were analysed according to intention to treat for all endpoints. This study is registered with ClinicalTrials.gov, number NCT00904813. Findings Between Oct 5, 1998, and Jan 31, 2013, 840 patients were recruited and randomised; 385 patients in the three-arm randomisation, of whom 129 patients were randomly assigned to short-course radiotherapy, 128 to short-course radiotherapy with delay, and 128 to long-course radiotherapy with delay, and 455 patients in the two-arm randomisation, of whom 228 were randomly assigned to short-course radiotherapy and 227 to short-course radiotherapy with delay. In patients with any local recurrence, median time from date of randomisation to local recurrence in the pooled short-course radiotherapy comparison was 33.4 months (range 18.2-62.2) in the short-course radiotherapy group and 19.3 months (8.5-39.5) in the short-course radiotherapy with delay group. Median time to local recurrence in the long-course radiotherapy with delay group was 33.3 months (range 17.8-114.3). Cumulative incidence of local recurrence in the whole trial was eight of 357 patients who received short-course radiotherapy, ten of 355 who received short-course radiotherapy with delay, and seven of 128 who received long-course radiotherapy (HR vs short-course radiotherapy: short-course radiotherapy with delay 1.44 [95% CI 0.41-5.11]; long-course radiotherapy with delay 2.24 [0.71-7.10]; p=0.48; both deemed non-inferior). Acute radiation-induced toxicity was recorded in one patient (<1%) of 357 after short-course radiotherapy, 23 (7%) of 355 after short-course radiotherapy with delay, and six (5%) of 128 patients after long-course radiotherapy with delay. Frequency of postoperative complications was similar between all arms when the three-arm randomisation was analysed (65 [50%] of 129 patients in the short-course radiotherapy group; 48 [38%] of 128 patients in the short-course radiotherapy with delay group; 50 [39%] of 128 patients in the long-course radiotherapy with delay group; odds ratio [OR] vs short-course radiotherapy: short-course radiotherapy with delay 0.59 [95% CI 0.36-0.97], long-course radiotherapy with delay 0.63 [0.38-1.04], p=0.075). However, in a pooled analysis of the two short-course radiotherapy regimens, the risk of postoperative complications was significantly lower after short-course radiotherapy with delay than after short-course radiotherapy (144 [53%] of 355 vs 188 [41%] of 357; OR 0.61 [95% CI 0.45-0.83] p=0.001). Interpretation Delaying surgery after short-course radiotherapy gives similar oncological results compared with short-course radiotherapy with immediate surgery. Long-course radiotherapy with delay is similar to both short-course radiotherapy regimens, but prolongs the treatment time substantially. Although radiation-induced toxicity was seen after short-course radiotherapy with delay, postoperative complications were significantly reduced compared with short-course radiotherapy. Based on these findings, we suggest that short-course radiotherapy with delay to surgery is a useful alternative to conventional short-course radiotherapy with immediate surgery.
引用
收藏
页码:336 / 346
页数:11
相关论文
共 34 条
  • [1] Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum Trans-Tasman Radiation Oncology Group Trial (TROG 01.04)
    Ansari, Nabila
    Solomon, Michael J.
    Fisher, Richard J.
    Mackay, John
    Burmeister, Bryan
    Ackland, Stephen
    Heriot, Alexander
    Joseph, David
    McLachlan, Sue-Anne
    McClure, Bev
    Ngan, Samuel Y.
    [J]. ANNALS OF SURGERY, 2017, 265 (05) : 882 - 888
  • [2] The 'good', the 'bad', and the 'ugly' rectal cancers
    Blomqvist, Lennart
    Glimelius, Bengt
    [J]. ACTA ONCOLOGICA, 2008, 47 (01) : 5 - 8
  • [3] Chemotherapy with preoperative radiotherapy in rectal cancer
    Bosset, Jean-Francois
    Collette, Laurence
    Calais, Gilles
    Mineur, Laurent
    Maingon, Philippe
    Radosevic-Jelic, Ljiljana
    Daban, Alain
    Bardet, Etienne
    Beny, Alexander
    Ollier, Jean-Claude
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (11) : 1114 - 1123
  • [4] Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer
    Braendengen, Morten
    Tveit, Kjell M.
    Berglund, Ake
    Birkemeyer, Elke
    Frykholm, Gunilla
    Pahlman, Lars
    Wiig, Johan N.
    Bystrom, Per
    Bujko, Krzysztof
    Glimelius, Bengt
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3687 - 3694
  • [5] Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
    Breugom, Anne J.
    Swets, Marloes
    Bosset, Jean-Francois
    Collette, Laurence
    Sainato, Aldo
    Cionini, Luca
    Glynne-Jones, Rob
    Counsell, Nicholas
    Bastiaannet, Esther
    van den Broek, Colette B. M.
    Liefers, Gerrit-Jan
    Putter, Hein
    van de Velde, Cornelis J. H.
    [J]. LANCET ONCOLOGY, 2015, 16 (02) : 200 - 207
  • [6] Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer
    Bujko, K.
    Nowacki, M. P.
    Nasierowska-Guttmejer, A.
    Michalski, W.
    Bebenek, M.
    Kryj, M.
    [J]. BRITISH JOURNAL OF SURGERY, 2006, 93 (10) : 1215 - 1223
  • [7] Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study
    Bujko, K.
    Wyrwicz, L.
    Rutkowski, A.
    Malinowska, M.
    Pietrzak, L.
    Krynski, J.
    Michalski, W.
    Oledzki, J.
    Kusnierz, J.
    Zajac, L.
    Bednarczyk, M.
    Szczepkowski, M.
    Tarnowski, W.
    Kosakowska, E.
    Zwolinski, J.
    Winiarek, M.
    Wisniowska, K.
    Partycki, M.
    Beczkowska, K.
    Polkowski, W.
    Stylinski, R.
    Wierzbicki, R.
    Bury, P.
    Jankiewicz, M.
    Paprota, K.
    Lewicka, M.
    Cisel, B.
    Skorzewska, M.
    Mielko, J.
    Bebenek, M.
    Maciejczyk, A.
    Kapturkiewicz, B.
    Dybko, A.
    Hajac, L.
    Wojnar, A.
    Lesniak, T.
    Zygulska, J.
    Jantner, D.
    Chudyba, E.
    Zegarski, W.
    Las-Jankowska, M.
    Jankowski, M.
    Kolodziejski, L.
    Radkowski, A.
    Zelazowska-Omiotek, U.
    Czeremszynska, B.
    Kepka, L.
    Kolb-Sielecki, J.
    Toczko, Z.
    Fedorowicz, Z.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (05) : 834 - 842
  • [8] Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery plus a fluoropyrimidine ± oxaliplatin
    Bujko, K.
    Glimelius, B.
    Valentini, V.
    Michalski, W.
    Spalek, M.
    [J]. EJSO, 2015, 41 (06): : 713 - 723
  • [9] CEDERMARK B, 1995, CANCER-AM CANCER SOC, V75, P2269, DOI 10.1002/1097-0142(19950501)75:9<2269::AID-CNCR2820750913>3.0.CO
  • [10] 2-I